Heart failure recovery: time to cut the pills?

NCT ID NCT06724653

Recruiting now Disease control Sponsor: Chungnam National University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at heart failure patients whose heart function has improved to normal levels. It tests whether gradually stopping one of their heart medications (RAS blocker or beta blocker) is safe, compared to staying on all medications. The goal is to see if patients can maintain their recovery without relapse. 150 adults are being recruited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: RAS blocker and beta blocker
What this could lead to: If successful, this could show that some heart failure patients with recovered heart function can safely take fewer medications without their condition worsening.
What could go wrong: This is a small, early-phase trial (150 people) and not yet proven. Tapering medication may cause heart function to decline again in some patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EJECTION FRACTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EJECTION FRACTION HEART FAILURE RECOVERY OF FUNCTION

Contacts and locations

Locations

Chungnam national university hospital
RECRUITING

Daejeon, Republic of Korea, 35015, South Korea
Jeonbuk national university hospital
RECRUITING

Jeonju, Jeollabuk-do, 54907, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.